NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC - With a proven biotech market leadership position, Novotech’s compelling value proposition drives its sustained success in delivering biotech clinical trials - Novotech-CRO.com
Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC

 

NewswireTODAY - /newswire/ - San Antonio, TX, United States, 2023/01/30 - With a proven biotech market leadership position, Novotech’s compelling value proposition drives its sustained success in delivering biotech clinical trials - Novotech-CRO.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan recently analyzed the Asia-Pacific contract research organization industry and, based on its findings, recognizes Novotech with the 2022 Asia-Pacific Contract Research Organization Company of the Year Award. The company has a regional presence across eleven Asia-Pacific (APAC) countries, including China, India, Thailand, Malaysia, Australia, and South Korea. Novotech has more than 2,500 team members providing end-to-end clinical development support to more than 600 biotechnology clients covering all clinical trial phases in APAC, Europe, and North America.

Novotech offers a 360-degree approach to drug development for its biotech clients from feasibility assessments to regulatory submission support, data management, medical monitoring, and project management. The full-service CRO works with the global biotech sector with a focus on conducting their clinical programs in APAC, offering expert teams with decades of operational knowledge along with advanced technology to facilitate exceptional clinical trial support.

The therapeutic area experience include:

• Oncology and Hematology
• Cell & Gene Therapy
• Neurology
• Cardiology
• Vaccines
• Endocrinology
• Immunology
• Infectious diseases
• Gastroenterology
• Respiratory illnesses

According to Azza Fazar, a Frost & Sullivan best practices research analyst,“Novotech has incorporated new technologies such as virtual trials, real-world evidence capabilities, and AI-driven clinical data, enabling it to add value to its services and undertake more extensive global trials. The company addresses the global drug development market’s unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation.”

Novotech invests and partners with various virtual clinical trial providers in APAC, such as ObvioHealth and Saama Technologies, to expand its virtual clinical trial capabilities. It also supported the biotech sector’s clinical trial activity throughout COVID-19, providing accelerated clinical programs in Asia-Pacific.

“Novotech fosters partnerships in APAC, Europe, and the United States to ensure that its clients always have access to the very best in clinical development programs. It has established long-standing customer relationships and remains a trusted partner with a reputation for offering the overall best in the market,” noted Fazar. With its customer-centric approach and strong overall performance, Novotech earns Frost & Sullivan’s 2022 Asia-Pacific Company of the Year Award in the contract research organization industry.

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards (frost.com) recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Novotech

Novotech (novotech-cro.com) is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities.

Novotech is the leading Asia Pacific centred biotech CRO with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2700 staff working across offices in 20 geographies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Novotech | Frost & Sullivan
Contact: Tammy Chan - Frost.com 
877-463-7678 tammy.chan[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)